Synonym
PF-06870961; PF-6870961; PF06870961; PF6870961; PF 06870961; PF 6870961;
IUPAC/Chemical Name
(R)-1-(2-(5-(2-hydroxy-6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethan-1-one
InChi Key
QVWZNQBFKUFFHO-RUZDIDTESA-N
InChi Code
1S/C29H32N6O2S/c1-18-11-24(32-27(37)30-18)21-3-5-23-20(12-21)4-6-25(23)35-16-29(17-35)7-9-33(10-8-29)26(36)13-22-15-34-14-19(2)38-28(34)31-22/h3,5,11-12,14-15,25H,4,6-10,13,16-17H2,1-2H3,(H,30,32,37)/t25-/m1/s1
SMILES Code
CC1=CN2C=C(CC(=O)N3CCC4(CN(C4)[C@@H]5CCC6=CC(=CC=C56)C7=NC(O)=NC(C)=C7)CC3)N=C2S1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
528.68
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Richardson RS, Sulima A, Rice KC, Kucharczk JA, Janda KD, Nisbett KE, Koob GF, Vendruscolo LF, Leggio L. Pharmacological GHSR (ghrelin receptor) blockade reduces alcohol binge-like drinking in male and female mice. Neuropharmacology. 2023 Nov 1;238:109643. doi: 10.1016/j.neuropharm.2023.109643. Epub 2023 Jun 25. PMID: 37369277; PMCID: PMC10513123.
2: Sulima A, Akhlaghi F, Leggio L, Rice KC. Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457. Bioorg Med Chem. 2021 Nov 15;50:116465. doi: 10.1016/j.bmc.2021.116465. Epub 2021 Oct 12. PMID: 34662828; PMCID: PMC9837661.
3: Deschaine SL, Hedegaard MA, Pince CL, Farokhnia M, Moose JE, Stock IA, Adusumalli S, Akhlaghi F, Hougland JL, Sulima A, Rice KC, Koob GF, Vendruscolo LF, Holst B, Leggio L. Initial Pharmacological Characterization of a Major Hydroxy Metabolite of PF-5190457: Inverse Agonist Activity of PF-6870961 at the Ghrelin Receptor. J Pharmacol Exp Ther. 2023 Aug;386(2):117-128. doi: 10.1124/jpet.122.001393. Epub 2023 Jan 11. PMID: 36631279; PMCID: PMC10353127.
4: Adusumalli S, Jamwal R, Obach RS, Ryder TF, Leggio L, Akhlaghi F. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach. Drug Metab Dispos. 2019 Aug;47(8):874-882. doi: 10.1124/dmd.119.087015. Epub 2019 Jun 10. PMID: 31182423; PMCID: PMC6636241.
5: Adusumalli S, Jamwal R, Leggio L, Akhlaghi F. Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Nov 1;1130-1131:121820. doi: 10.1016/j.jchromb.2019.121820. Epub 2019 Oct 8. PMID: 31670107.
